{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:44:34Z","timestamp":1762623874737,"version":"build-2065373602"},"reference-count":15,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients requiring an interruption in dual\u2010antiplatelet therapy (<jats:styled-content style=\"fixed-case\">DAPT<\/jats:styled-content>) within 6 months of cardiac stenting are at risk for thrombotic events. Bridging with short\u2010acting intravenous antiplatelet agents has been proposed to minimize the risk of thrombotic and hemorrhagic complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective analysis of a tirofiban bridging strategy did not use an initial bolus loading dose. Tirofiban infusions were initiated 24\u201348 hours after the last oral antiplatelet dose at a rate of 0.1 \u03bcg\/kg\/min (or 0.05 \u03bcg\/kg\/min if renal dysfunction) and continued until 4\u20138 hours before surgery or until <jats:styled-content style=\"fixed-case\">DAPT<\/jats:styled-content> could be resumed. Coprimary end points were occurrence of major adverse cardiac events (<jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>) and bleeding.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty patients requiring <jats:styled-content style=\"fixed-case\">DAPT<\/jats:styled-content> interruption within 6 months of cardiac stenting for either a surgical procedure or who were unable to take any medications by mouth were included. The median time from stent implantation to <jats:styled-content style=\"fixed-case\">DAPT<\/jats:styled-content> interruption was 33 days (range 3\u2013146 days). Two patients experienced a <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content> during their hospital stay. No major bleeding events occurred; minor bleeding occurred in four patients during tirofiban therapy. Five patients in this analysis had end\u2010stage renal disease requiring hemodialysis. Of these patients, no <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content> or major bleeding events occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This analysis observed that a tirofiban bridging strategy without an initial bolus loading dose has comparable efficacy and safety as previously published reports. A tirofiban infusion without bolus dosing may be a safe option for antiplatelet bridging in patients with a recent cardiac stent implant to prevent stent thrombosis.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.1956","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T21:06:35Z","timestamp":1495573595000},"page":"888-892","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bridging with Tirofiban during Oral Antiplatelet Interruption: A Single\u2010Center Case Series Analysis Including Patients on Hemodialysis"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0354-3559","authenticated-orcid":false,"given":"Elizabeth A.","family":"Walker","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of California Davis Medical Center Sacramento California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Dager","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of California Davis Medical Center Sacramento California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.019"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.005"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.513"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.046"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-011-0197-y"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aep373"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04456.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2015.11.085"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0b013e3283645c79"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(88)90158-1"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-013-1041-8"},{"key":"e_1_2_6_15_1","unstructured":"Clinical Pharmacology Review.NDA No 20\u2010912. Available fromhttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/99\/backgrd\/3555b1m.pdf. Accessed July 12 2016."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.2002"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1956","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:53:03Z","timestamp":1761047583000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1002\/phar.1956"],"URL":"https:\/\/doi.org\/10.1002\/phar.1956","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2017,7,6]]},"assertion":[{"value":"2017-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}